Christopher Ruel
Impact in
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
- Immunology top 10%
- Immunotherapy and Immune Responses
Papers in
- Oncology 21
- Cancer Treatment and Pharmacology 8
- Cancer Immunotherapy and Biomarkers 7
- CAR-T cell therapy research 5
- HER2/EGFR in Cancer Research 4
-
- Protein Degradation and Inhibitors 5
- Co-authors
- Paul Frankel (36 shared papers)David R. Gandara (5 shared papers)Przemyslaw Twardowski (8 shared papers)Primo N. Lara (7 shared papers)Marianna Koczywas (5 shared papers)Chandra P. Belani (1 shared paper)Suresh S. Ramalingam (1 shared paper)Barbara J. Gitlitz (1 shared paper)
- Journals
- Journal of Clinical Oncology (13 papers)Cancer (4 papers)The Oncologist (3 papers)Blood (3 papers)International Journal of Radiation Oncology*Biology*Physics (2 papers)
- Partner nations
- United StatesMalaysiaIndonesia
In The Last Decade
Christopher Ruel
46 papers receiving 1.2k citations
Peers
Comparison fields: 5 of 71
- Oncology 536
- Immunology 203
- Pulmonary and Respiratory Medicine 276
- Cancer Research 124
- Hematology 84
Countries citing papers authored by Christopher Ruel
This map shows the geographic impact of Christopher Ruel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Ruel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Ruel more than expected).
Fields of papers citing papers by Christopher Ruel
This network shows the impact of papers produced by Christopher Ruel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Ruel. The network helps show where Christopher Ruel may publish in the future.
Co-authors
The 25 scholars most cited alongside Christopher Ruel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 51 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2009 | 140 | |
| 2 | 2004 | 90 | |
| 3 | 2019 | 88 | |
| 4 | 2021 | 69 | |
| 5 | 2010 | 69 | |
| 6 | 2011 | 67 | |
| 7 | 2020 | 63 | |
| 8 | 2013 | 60 | |
| 9 | 2015 | 59 | |
| 10 | 2018 | 56 | |
| 11 | Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial. | 2009 | 46 |
| 12 | 2015 | 45 | |
| 13 | 2007 | 33 | |
| 14 | 2015 | 30 | |
| 15 | 2006 | 26 | |
| 16 | 2008 | 26 | |
| 17 | 2019 | 25 | |
| 18 | 2011 | 22 | |
| 19 | 2014 | 22 | |
| 20 | 2008 | 21 |
About Christopher Ruel
Christopher Ruel is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research and Hematology, having authored 51 papers that have together received 1.2k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (8 papers), Cancer Immunotherapy and Biomarkers (7 papers), Multiple Myeloma Research and Treatments (6 papers), Protein Degradation and Inhibitors (5 papers), Advanced Breast Cancer Therapies (5 papers), CAR-T cell therapy research (5 papers), HER2/EGFR in Cancer Research (4 papers) and Renal cell carcinoma treatment (3 papers). The work is most often cited by research in Oncology (536 citations), Immunology (203 citations), Pulmonary and Respiratory Medicine (276 citations), Cancer Research (124 citations) and Hematology (84 citations). Christopher Ruel has collaborated with scholars based in United States, Malaysia and Indonesia. Frequent co-authors include Paul Frankel, David R. Gandara, Przemyslaw Twardowski, Primo N. Lara, Marianna Koczywas, Chandra P. Belani, Suresh S. Ramalingam, Barbara J. Gitlitz, Igor Espinoza‐Delgado and Edward M. Newman. Their work appears in journals such as Journal of Clinical Oncology, Cancer, The Oncologist, Blood and International Journal of Radiation Oncology*Biology*Physics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.